Stryker Q2 2026: net sales $6.6B (+9.4%), adj EPS $3.69 (+17.9%), narrows FY guidance

STRYKER CORP

Q2 net sales $6.6B, up 9.4% reported and 9.0% organic; MedSurg/Neuro +9.2% organic, Orthopaedics +8.6%.
Reported EPS $3.30 (+44.1%), adjusted EPS $3.69 (+17.9%); adjusted operating margin 27.4% (+170 bps).
FY 2026 guidance narrowed: organic sales growth 8.3%-9.3%, adjusted EPS $14.95-$15.10.
CEO cites recovery from cyber incident and strong execution; momentum regained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.